Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Washington for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Washington only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Washington (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Saritha Thumma (NPI 1952445223)

Field	Value
Entity Type	Individual
Organization	Saritha Thumma
Address	601 S Sherman St
City	Spokane
State	WA
ZIP	99202
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	February 19, 2007

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

This provider is highly specialized in oncology drug administration: the top revenue drivers are oncology and related injectable therapies such as J9271 (pembrolizumab), J9144 (daratumumab), and J0897 (denosumab), and chemotherapy administration codes like 96413 and 96401 also appear in the mix. The presence of high-volume biologic and chemotherapy J‑codes plus E/M visits indicates a clinic-based oncology practice that delivers infusions and injectables as a core service line.

Medicare revenue is concentrated in a very small set of items: the precomputed top-3 Medicare codes account for 79.8% of this provider's total Medicare revenue, with J9271 alone representing $602.2K (33.3%) and J9144 $592.8K (32.8%). This level of concentration implies the practice’s financial performance is closely tied to utilization and reimbursement of a few high-cost oncology agents.

The provider effectively operates as a single-payer practice from the available data: total Medicare revenue is $1.8M while there is no Medicaid billing on file. This means payer mix is heavily skewed toward Medicare beneficiaries and any analysis of patient population or revenue risk should treat Medicaid as absent in the payer portfolio.

On competitive standing, the provider shows mixed national placement across top codes: for J9144 the provider ranks #78 of 615 (87th percentile), indicating above-typical national activity for daratumumab administration; in contrast, J9271 ranks #757 of 1841 (59th percentile), a typical national volume for pembrolizumab. Several supportive and infusion-related codes (e.g., 96375, 96372, 36415) are at high percentiles or noted as "notably above typical," suggesting strong throughput for infusion services relative to peers.

There are clear statistical outliers in specific ancillary and administration codes: 96402 ranks #54 of 4765 providers nationally and is labeled an "extreme outlier, far above typical national volume," and J3489 (zoledronic acid) ranks #48 of 3032 and is also an "extreme outlier, far above typical national volume." These flags suggest this clinician bills substantially more of certain administration or supportive therapy codes than the typical national provider.

Evaluation and management volumes are above typical for many E/M levels: 99214 ranks in the 97th percentile and 99215 also in the 97th percentile nationally, indicating relatively high volumes of moderate-to-high complexity established outpatient visits. This supports a model where the provider manages ongoing, complex oncology care rather than only episodic procedures.

Tenure is long and may support established referral patterns: the NPI was enumerated on 2007-02-19 (~19 years ago), which indicates sustained practice presence in the market and likely established relationships with referral sources and infusion infrastructure.

Procedure mix shows comprehensive cancer care elements beyond high-cost drugs: imaging (74177, 71260), lab work (85025, 85027, 36415), and infusion-related codes (96365, 96361, 96375) are present among the top codes. This pattern suggests on-site diagnostic and supportive services that complement the chemotherapy/biologic infusion business model and may increase per-patient revenue capture.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

48 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	14,000	$40	$602.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	16,020	$40	$592.8K
J0897	Injection, denosumab, 1 mg	13,740	$20	$247.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	930	$90	$82.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	380	$140	$51.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	470	$100	$48.8K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,390	$20	$30.6K
J9395	Injection, fulvestrant, 25 mg	2,860	$10	$22.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	230	$60	$13.6K
J0185	Injection, aprepitant, 1 mg	13,260	$1	$13.3K

Showing 1–10 of 48

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 48 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Washington Distribution

Saritha Thumma — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Washington

Full comparison — all codes billed, vs. state median

48 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	30	9,600	$40	$465.7K
J9144	2	10	6,480	$40	$357.9K
J0897	6	150	1,800	$20	$57.9K
J3490	5	70	70	$50	$51.2K
Q5119	4	10	1,460	$20	$43.9K
96413	7	160	80	$110	$15K
J9395	1	10	1,890	$10	$14.6K
99214	149	10,860	100	$80	$13.6K
74177	368	550	110	$80	$12.3K
J9041	2	10	3,080	$1	$11.2K

Showing 1–10 of 48

Related Providers

Other providers that share a Tax Identification Number (TIN) with Saritha Thumma, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Douglas, Grant, Lincoln & Okanogan Counties Public Hospital District 6	WA	Critical Access Hospital	$0	$11.6M
Douglas, Grant, Lincoln & Okanogan Counties Public Hospital District 6	WA	Rural Health Clinic/Center	$0	$10.5M
St. Joseph Hospital LLC	ID	General Acute Care Hospital	$0	$4.7M
Cancer Care Northwest Centers P S	WA	Hematology & Oncology Physician	$0	$3M
Danko Martincic	ID	Hematology & Oncology Physician	$2.6M	$0
Columbia Surgical Specialists, Ps	WA	Ambulatory Surgical Clinic/Center	$891.1K	$1.2M
Vijay Narendran	FL	Hematology & Oncology Physician	$2M	$0
Hakan Kaya	WA	Medical Oncology Physician	$1.8M	$0
Christopher Lee	WA	Radiation Oncology Physician	$1.7M	$0
Elizabeth Gunderson	WA	Medical Oncology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as Saritha Thumma, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Multicare Health System	WA	Internal Medicine Physician	$0	$46.6M
Frontier Behavioral Health	WA	Community/Behavioral Health Agency	$0	$34.3M
Dungarvin Washington Children's Services, LLC	WA	Developmental Disabilities Clinic/Center	$0	$21.3M
Community Health Association Of Spokane	WA	Federally Qualified Health Center (FQHC)	$0	$8.2M
Providence Health & Services- Washington	WA	Rehabilitation Hospital	$0	$8M
Compass Career Solutions LLC	WA	Developmentally Disabled Services Day Training Agency	$0	$7.7M
Inland Imaging LLC	WA	Diagnostic Radiology Physician	$0	$6.8M
Northwest Autism Center	WA	Community/Behavioral Health Agency	$0	$5.9M
Northwest Pediatric Ophthalmology	WA	Ophthalmology Physician	$0	$4.2M
Inland Northwest Renal Care Group, LLC	WA	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$4.1M

Saritha Thumma — Billing Profile & Reimbursement Data

Sign up for Saritha Thumma — Billing Profile & Reimbursement Data policy alerts

Saritha Thumma — Billing Profile & Reimbursement Data

Sign up for Saritha Thumma — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References